Clinical Trial Update: Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating infliximab or vedolizumab to treat immune checkpoint inhibitor-related colitis in patients with genitourinary cancers or m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colitis
• Genitourinary Neoplasms
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Infliximab (infliximab)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colitis, Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING